Type 1 Diabetes Clinical Trial
— IDCLTrainingOfficial title:
Pilot Evaluation Study of the Feasibility of a Permanent Use in Free-life of inControl Artificial Pancreas System for the Treatment of Type 1 Diabetes
NCT number | NCT02892604 |
Other study ID # | 9722 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | November 24, 2015 |
Est. completion date | June 24, 2017 |
Verified date | December 2021 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A new version of the DiAs artificial pancreas (AP) system has been developed in view of wide scale outpatient trials. Denominated as inControl , it includes improved user interface and communication modules while closed-loop algorithms remain similar. During this pilot study, the investigators will evaluate this new version of AP for a two-week period during which the patients will use it for closed-loop insulin delivery 24/7 The main goal is train the clinical team with the new system and collect patient opinions on system acceptance from questionnaires. If this trial is conclusive, a randomized 6-month multicentre study including 240 patients will be initiated. A total of 5 patients will be included in this training study over a 4-week period.
Status | Terminated |
Enrollment | 3 |
Est. completion date | June 24, 2017 |
Est. primary completion date | June 24, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Type 1 diabetes mellitus since more than one year, treated by insulin since at least one year - Treatment by insulin pump since at least 6 months - Glycated hemoglobin (HbA1c) below 10.5% at inclusion visit - For women of child bearing age, no current pregnancy and use of an efficient contraception during the whole research participation - Agreement on no use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs, except if this therapy has been used for at least 3 months before study start - Agreement on stopping closed-loop insulin delivery after acetaminophen use and 4 following hours - Agreement on suspending use of patient CGM device during the study period while study CGM will be used - Access to the internet and a mobile phone network at home - Agreement on following study procedures - Affiliation to the French social security system or a similar healthcare coverage system - Mandatory written informed consent Exclusion Criteria: - Need for chronic use of acetaminophen - Start of use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs during the 3 months before inclusion - Hemophilia or other coagulation disorders - Psychological and/or cognitive troubles which may impair the appropriate following of study procedures - Diabetic ketoacidosis during the last 6 months - Acute cardiovascular event during the last 12 months - Severe hypoglycaemia with convulsions or loss of conscience during the last 12 months - Use of a therapy with significant impact on glucose metabolism - Cystic fibrosis - Lack of nearby third-party assistance availability in case of troubles - Malignant disease, except if considered as cured since at least 10 years - Impaired kidney function (serum creatinin > 150 umol/L) - Impaired liver status (ALAT or ASAT > 2-times upper normal limit) - Active gastroparesis - Acute adrenocortical event - Alcohol or narcotics abuse |
Country | Name | City | State |
---|---|---|---|
France | UHMontpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier | Jaeb Center for Health Research, MEDBIOMED, Montpellier, France, University of Virginia |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent time of active insulin closed-loop delivery | Percent time while AP system is active permanently | 2 weeks | |
Secondary | Percent time with blood glucose in target range | Percent time while blood glucose is kept in safe 70-180 mg/dl range | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|